Литература. 
Терапевтические возможности влияния на баланс цитокинов при заболеваниях кишечника и печени

1. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn’s disease: a user’s guide for clinicians. Am J Gastroenterol. 2002;97:2962−2972.

2. Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomized controlled trial. Gut. 2003;52:998−1002.

3. Sandborn WJ, Feagan B, Randford-Smith G et al. Randomized, placebo-controlled trial of CDP571, a humanized monoclonal antibody to TNF-?, in patients with moderate to severe Crohn’s disease [abstract]. Gastroenterology. 2003; 124: A61.

4. Sandborn WJ, Feagan BG, Hanauer SB et al. An engineered human antibody to TNF (CDP571) for active Crohn’s disease: a randomized double-blind placebo-controlled trial. Gastroenterology. 2001; 120:1330−1338.

5. Evans RC, Clarke L., Heath P et al. Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571. Aliment Pharmacol Ther. 1997;11:1031−1035.

6. Schreiber S, Winter T, Innes A et al. Safety of CDP 870, a pegylated anti-TNF antibody fragment in Crohn’s disease [abstract]. The CDP 870 Crohn’s disease Study Group. Am J Gastroenterol. 2003;98:S246.

7. Sandborn WJ, Hanauer SB, Katz S et al. Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001; 121:1088−1094.

8. Rutgeerts P, Lemmens L, Van Assche et al. Treatment of active Crohn’s disease with onercept (recombinant human soluble p55 tumor necrosis factor receptor): results of randomized open-label pilot study. Aliment Pharmacol Ther. 2003;17:185−192.

9. Ito H, Takazoe M, Fukuda Y et al. Effective treatment of active Crohn’s disease with humanized monoclonal antibody MRA to interleukin-6 receptor: a randomized placebo-controlled trial [abstract]. Gastroenterology. 2003;124:A25.

10. Van Assche G, Dalle I, Noman M et al. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol. 2003;98:369−376.

11. Creed TJ, Norman MR, Probert CS et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther. 2003;18:65−75.

12. Schreiber S, Fedorak RN, Nielsen OH et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn’s disease. Crohn’s disease IL-10 Cooperative Study Group. Gastroenterology. 2000;119:1461−1472.

13. Sands Be, Winston BD, Salzberg B et al. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn’s disease. Aliment Pharmacol Ther. 2002;16:399−406.

14. Rutggerts P, Reinisch W, Colombel JF et al. Preliminary results of a phase I/II study of Huzaf, an anti-IFN-monoclonal antibody, in patients with moderate to severe active Crohn’s disease [abstract]. Gastroenterology. 2002;122:A61.

15. Spahr L., Rubbia-Brandt L., Frossard J.-L. et al. Combination of steroids with ifliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J. Hepatol. 2002; 37: 448−455.

16. Tilg H., Jalan R., Kaser A. et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J. Hepatol. 2003; 38: 419−425.

17. Tilg H., Kaser A. Management of acute alcoholic hepatitis // In: Prevention and Intervention in Liver Disease. I-EASL Postgraduate Course. Madrid. 2002: 28−37.

18. Adams L.A., Zein C.O., Angulo P., Lindor K.D. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2004; 99: 2356−2358.

19. Epstein M.P., Kaplan M.M. A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Dig. Dis. Sci. 2004; 49: 1−4.

20. Melson D.R., Tu Z., Soldevia-Pico C. et al. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology. 2003; 38: 859−868.